Stockscreener 앱 받기
60.55
14.61%
7.72
시장 영업 전:
61.84
1.29
+2.13%
전일 마감가:
$52.83
열려 있는:
$56.08
하루 거래량:
1.10M
Relative Volume:
2.43
시가총액:
$1.68B
수익:
$169.47M
순이익/손실:
$-84.63M
주가수익비율:
-21.48
EPS:
-2.8189
순현금흐름:
$-145.42M
1주 성능:
+9.87%
1개월 성능:
+25.16%
6개월 성능:
+187.10%
1년 성능:
+297.05%
1일 변동 폭
$54.17
$62.69
1주일 범위
$52.68
$62.69
52주 변동 폭
$15.12
$62.69
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
60.55 | 1.46B | 169.47M | -84.63M | -145.42M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus
AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Canada
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - simplywall.st
AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - Yahoo Finance
AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com
AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today
AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat
H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada
Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com
AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq
HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus
Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates - Bitget
AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Mil - GuruFocus
AnaptysBio earnings beat by $0.71, revenue topped estimates - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
AnaptysBio Q4 Swings to Profit, Revenue Rises - marketscreener.com
AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan - TradingView
AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 71c - StreetInsider
Anaptysbio 10-K: $234.6M Revenue, $(0.46) EPS - TradingView
Planned AnaptysBio (NASDAQ: ANAB) split separates royalties from pipeline - Stock Titan
AnaptysBio, Inc. Announces Spin-off of Biopharma Operations to Form First Tracks Biotherapeutics, Targeting Q2 2026 - Quiver Quantitative
Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q4 Revenue $108.2M, vs. FactSet Est of $87.0M - marketscreener.com
AnaptysBio (NASDAQ: ANAB) Q4 profit, royalties surge and 2026 spin-off - Stock Titan
Commit To Buy AnaptysBio At $35, Earn 15.9% Annualized Using Options - Nasdaq
ANAB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ANAB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AnaptysBio, Inc. (ANAB) Stock Analysis: A Biotech With 21% Potential Upside - DirectorsTalk Interviews
FDA accepts Vanda’s imsidolimab application for rare skin disorder - Investing.com
FDA accepts Vanda’s imsidolimab application for rare skin disorder By Investing.com - Investing.com UK
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - ChartMill
AnaptysBio stock hits 52-week high at $57.73 By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $57.73 - Investing.com
Big Picture: Can AnaptysBio Inc grow without external fundingWeekly Trade Review & Proven Capital Preservation Tips - baoquankhu1.vn
How Anaptysbio Inc. (ANAB) Affects Rotational Strategy Timing - Stock Traders Daily
Skandinaviska Enskilda Banken AB publ Has $4.45 Million Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. (ANAB) Investor Outlook: Analyzing a 22.46% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
AnaptysBio (ANAB) to Release Quarterly Earnings on Thursday - Defense World
AnaptysBio, Inc. $ANAB Stock Holdings Trimmed by GSA Capital Partners LLP - MarketBeat
ANAB PE Ratio & Valuation, Is ANAB Overvalued - Intellectia AI
AnaptysBio (NASDAQ:ANAB) Insider Sells $540,000.00 in Stock - MarketBeat
AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking the 23.71% Potential Upside for Investors - DirectorsTalk Interviews
AnaptysBio Insider Sells $540,000 in Stock - National Today
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - MarketBeat
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anaptysbio Inc 주식 (ANAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Feb 11 '26 |
Sale |
54.00 |
10,000 |
540,000 |
12,835 |
0.11%
6.00%
자본화:
|
볼륨(24시간):